Generated Narrative: ValueSet canshare-sact-regimen-code

This value set includes codes based on the following rules:

• Include codes fromhttp://snomed.info/sct where constraint = < 61371000210101 |Systemic anti cancer therapy regimen (regime/therapy)|
• Include these codes as defined in http://canshare.co.nz/fhir/CodeSystem/snomed-unpublished

  Code	Display
  392611000210105	BR Metastatic - cARBOplatin [2 AUC] and gemcitabine
  392601000210108	BR Metastatic - ribociclib
  392591000210103	LEU - GMALL T-LBL 1/2004 HDMTX/ASP [55 years and under]
  392581000210100	LEU - GMALL T-LBL 1/2004 Consolidation [55 years and under]
  392571000210102	LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [55 years and under]
  392561000210108	LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [55 years and under]
  392551000210105	LEU - GMALL T-LBL 1/2004 triple prophylaxis
  392541000210107	LEU - GMALL T-LBL 1/2004 CYCLO/ARAC
  392531000210104	LEU - GMALL T-LBL 1/2004 VM26/ARAC
  392521000210101	LEU - GMALL T-LBL 1/2004 Reinduction
  392511000210106	LEU - GMALL T-LBL 1/2004 HDMTX/ASP [over 55 years]
  392501000210109	LEU - GMALL T-LBL 1/2004 Consolidation I [over 55 years]
  392491000210104	LEU - GMALL T-LBL 1/2004 Pre-phase and Induction [over 55 years]
  392481000210101	LEU ALL precursor T-cell - GMALL T-LBL 1/2004 [over 55 years]
  392471000210103	LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis High Risk
  392461000210109	LEU - HyperCVAD with pegaspargase [under 40 years] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]
  392451000210106	LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis High Risk
  392441000210108	LEU - HyperCVAD with pegaspargase [under 40 years] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]
  392431000210100	LEU ALL - HyperCVAD with pegaspargase Part A and B followed by POMP Maintenance [under 40 years]
  392421000210102	LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Consolidation/delayed intensification [Cycle 3]
  392411000210107	LEU - UKALL14 with RITUximab [over 40 years] [not for transplant] Intensification/CNS prophylaxis
  392401000210105	LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [not for transplant]
  392391000210107	LEU - UKALL14 with RITUximab [not for transplant] Maintenance
  392381000210105	LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Consolidation/delayed intensification [Cycle 3]
  392371000210108	LEU - UKALL14 with RITUximab [40 years and under] [not for transplant] Intensification/CNS prophylaxis
  392361000210102	LEU - UKALL14 with RITUximab [not for transplant] Phase 2 Induction
  392351000210100	LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [not for transplant]
  392341000210103	LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis High Risk
  392331000210106	LEU - HyperCVAD with RITUximab [60 years and under] Part B with Intrathecal CNS prophylaxis Unknown Risk [default]
  392321000210109	LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis High Risk
  392311000210104	LEU - HyperCVAD with RITUximab [60 years and under] Part A with Intrathecal CNS prophylaxis Unknown Risk [default]
  392301000210101	LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [60 years and under]
  392291000210100	LEU - HyperCVAD with RITUximab [over 60 years] Part B with Intrathecal CNS prophylaxis High Risk
  392281000210102	LEU - HyperCVAD Part B with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]
  391941000210106	LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis High Risk
  391931000210103	LEU - HyperCVAD Part A with RITUximab [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]
  391921000210100	LEU ALL precursor B-cell - HyperCVAD with RITUximab Part A and B followed by POMP Maintenance [over 60 years]
  391911000210105	LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Consolidation/delayed intensification [Cycle 3]
  391901000210108	LEU - UKALL14 with RITUximab [40 years and under] Consolidation [Cycle 1 and 2]
  391891000210107	LEU - UKALL14 with RITUximab [40 years and under] [for transplant] Intensification/CNS prophylaxis
  391881000210105	LEU - UKALL14 with RITUximab [40 years and under] Phase 1 Induction
  391871000210108	LEU ALL precursor B-cell - UKALL14 with RITUximab [40 years and under] [for transplant]
  391861000210102	LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [40 years and under]
  391851000210100	LEU - UKALL14 Consolidation [Cycle 1] [40 years and under]
  391841000210103	LEU - UKALL14 Intensification/CNS prophylaxis [40 years and under]
  391831000210106	LEU - UKALL14 Phase 1 Induction [40 years and under]
  391821000210109	LEU ALL - UKALL14 [40 years and under]
  391811000210104	LEU - UKALL14 with RITUximab Consolidation [Cycle 4]
  391801000210101	LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Consolidation/delayed intensification [Cycle 3]
  391791000210100	LEU - UKALL14 with RITUximab [over 40 years] Consolidation [Cycle 1 and 2]
  391781000210102	LEU - UKALL14 with RITUximab [over 40 years] [for transplant] Intensification/CNS prophylaxis
  391771000210104	LEU - UKALL14 with RITUximab [for transplant] Phase 2 Induction
  391761000210105	LEU - UKALL14 with RITUximab [over 40 years] Phase 1 Induction
  391751000210107	LEU ALL precursor B-cell - UKALL14 with RITUximab [over 40 years] [for transplant]
  391741000210109	LEU - AIDA consolidation 3 [over 70 years]
  391731000210101	LEU - AIDA consolidation 2 [over 70 years]
  391721000210103	LEU - AIDA consolidation 1 [over 70 years]
  391711000210108	LEU - AIDA induction [over 70 years]
  391701000210106	LEU APL - AIDA induction and consolidations 1, 2 and 3 [over 70 years]
  391691000210106	LEU AML - DA+GO-1 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]
  391681000210109	LEU - Pethema LPA2005 maintenance [70 years and under] [low risk]
  391671000210107	LEU - Pethema LPA2005 consolidation 3 [70 years and under] [low risk]
  391661000210101	LEU - Pethema LPA2005 consolidation 2 [70 years and under] [low risk]
  391621000210108	LEU - Pethema LPA2005 consolidation 1 [70 years and under] [low risk]
  391601000210100	LEU - Pethema LPA2005 induction [70 years and under] [low risk]
  391591000210105	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [low risk]
  391581000210108	LEU - Pethema LPA2005 maintenance [over 70 years] [low risk]
  391571000210106	LEU - Pethema LPA2005 consolidation 3 [over 70 years] [low risk]
  391561000210100	LEU - Pethema LPA2005 consolidation 2 [over 70 years] [low risk]
  391551000210103	LEU - Pethema LPA2005 consolidation 1 [over 70 years] [low risk]
  391541000210101	LEU - Pethema LPA2005 induction [over 70 years] [low risk]
  391531000210109	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [low risk]
  391521000210107	LEU - Pethema LPA2005 maintenance [over 70 years] [high risk]
  391511000210102	LEU - Pethema LPA2005 consolidation 3 [over 70 years] [high risk]
  391501000210104	LEU - Pethema LPA2005 consolidation 2 [over 70 years] [high risk]
  391491000210109	LEU - Pethema LPA2005 consolidation 1 [over 70 years] [high risk]
  391481000210107	LEU - Pethema LPA2005 induction [over 70 years] [high risk]
  391471000210105	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [high risk]
  391461000210104	GU GCT Seminoma Adjuvant - cARBOplatin [7 AUC]
  391451000210102	GU URO Advanced - cISplatin and gemcitabine
  391441000210100	GU URO Advanced - cISplatin [split dose] and gemcitabine
  391431000210108	GU Upper Tract Urothelial Adjuvant - cISplatin [split dose] and gemcitabine
  391421000210106	GU GCT Metastatic - TIP [PACLItaxel, IFOSFamide and cISplatin]
  391411000210101	LEU - Pethema LPA2005 maintenance [over 70 years] [intermediate risk]
  312741000210103	LEU - Pethema LPA2005 consolidation 3 [over 70 years] [intermediate risk]
  312731000210106	LEU - Pethema LPA2005 consolidation 2 [over 70 years] [intermediate risk]
  312721000210109	LEU - Pethema LPA2005 consolidation 1 [over 70 years] [intermediate risk]
  312711000210104	LEU - Pethema LPA2005 induction [over 70 years] [intermediate risk]
  312701000210101	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [over 70 years] [intermediate risk]
  312691000210101	LEU - Pethema LPA2005 maintenance [under 60 years] [high risk]
  312681000210103	LEU - Pethema LPA2005 consolidation 3 [under 60 years] [high risk]
  312671000210100	LEU - Pethema LPA2005 consolidation 2 [under 60 years] [high risk]
  312661000210106	LEU - Pethema LPA2005 consolidation 1 [under 60 years] [high risk]
  312651000210108	LEU - Pethema LPA2005 induction [under 60 years] [high risk]
  312631000210102	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [under 60 years] [high risk]
  312621000210104	LEU - Pethema LPA2005 maintenance [60 to 70 years] [high risk]
  312611000210109	LEU - Pethema LPA2005 consolidation 3 [60 to 70 years] [high risk]
  312601000210107	LEU - Pethema LPA2005 consolidation 2 [60 to 70 years] [high risk]
  312591000210102	LEU - Pethema LPA2005 consolidation 1 [60 to 70 years] [high risk]
  312581000210104	LEU - Pethema LPA2005 induction [60 to 70 years] [high risk]
  312571000210101	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [60 to 70 years] [high risk]
  312561000210107	LEU - UKALL14 Maintenance
  312551000210109	LEU - UKALL14 Consolidation [Cycle 4]
  312541000210106	LEU - UKALL14 Consolidation/delayed intensification [Cycle 3] [over 40 years]
  312531000210103	LEU - UKALL14 Consolidation [Cycle 2]
  312521000210100	LEU - UKALL14 Consolidation [Cycle 1] [over 40 years]
  312511000210105	LEU - UKALL14 Intensification/CNS prophylaxis [over 40 years]
  312501000210108	LEU - UKALL14 - Phase 2 Induction
  312491000210103	LEU - UKALL14 [over 40 years] - Phase 1 Induction
  312481000210100	LEU ALL - UKALL14 [over 40 years]
  312471000210102	LYM NHL B-cell - O-CHOP21 [oBINUTUZumab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
  312461000210108	LYM - DA-R-EPOCH LEVEL 6
  312451000210105	LYM - DA-R-EPOCH LEVEL 5
  312441000210107	LYM - DA-R-EPOCH LEVEL 4
  312431000210104	LYM - DA-R-EPOCH LEVEL 3
  312421000210101	LYM - DA-R-EPOCH LEVEL 2
  312411000210106	LYM - DA-R-EPOCH LEVEL minus 3
  312401000210109	LYM - DA-R-EPOCH LEVEL minus 2
  312391000210106	LYM - DA-R-EPOCH LEVEL minus 1
  312381000210109	LYM - DA-R-EPOCH LEVEL 1
  312371000210107	LYM NHL B-cell - DA-R-EPOCH [Dose-adjusted RITUximab, etoposide, prEDNIsone, vinCRISTine, CYCLOPHOSPHamide and DOXOrubicin] [9 levels]
  312361000210101	LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis High Risk
  312351000210104	LEU - HyperCVAD Part B [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]
  312341000210102	LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis High Risk
  312331000210105	LEU - HyperCVAD Part A [60 years and under] Intrathecal CNS prophylaxis Unknown Risk [default]
  312321000210108	LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [60 years and under]
  312311000210103	LEU - HyperCVAD POMP Maintenance
  312301000210100	LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis High Risk
  312291000210104	LEU - HyperCVAD Part B [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]
  312281000210101	LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis High Risk
  312271000210103	LEU - HyperCVAD Part A [over 60 years] Intrathecal CNS prophylaxis Unknown Risk [default]
  312261000210109	LEU ALL - HyperCVAD Part A and B followed by POMP Maintenance [over 60 years]
  312251000210106	SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q2W]
  312241000210108	SAR Ewing sarcoma - VAC, VC and IE [Q2W]
  312231000210100	SAR - VAC + VV [vinCRISTine day 1, 8 and 15, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]
  312221000210102	SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide] ARST0431 [high risk]
  312211000210107	SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q3W] ARST0431 [high risk]
  312201000210105	SAR - IE [IFOSFamide and etoposide] [Q3W] ARST0431 [high risk]
  312191000210108	SAR - IE [IFOSFamide and etoposide] [Q2W] ARST0431 [high risk]
  312181000210106	SAR - VDC + V [vinCRISTine days 1 and 8, DOXOrubicin and CYCLOPHOSPHamide] [Q2W] ARST0431 [high risk]
  312171000210109	SAR - vinCRISTine days 1 and 8 and irinotecan ARST0431 [high risk]
  312161000210103	SAR - vinCRISTine days 1, 8 and 15 and irinotecan ARST0431 [high risk]
  312151000210101	SAR Rhabdomyosarcoma - vinCRISTine, irinotecan, IFOSFamide, etoposide, DOXOrubicin, CYCLOPHOSPHamide and daCTINomycin [ARST0431] [high risk]
  312141000210104	SAR - VAC [vinCRISTine, daCTINomycin and CYCLOPHOSPHamide][Q3W]
  312131000210107	SAR Ewing sarcoma - VAC, VC and IE [Q3W]
  312121000210105	SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q3W]
  312111000210100	SAR - IE [IFOSfamide and etoposide][Q3W]
  312101000210102	SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] [Q3W]
  312091000210109	SAR Ewing sarcoma - VDC, VC and IE [Q3W]
  312081000210107	SAR - MA [metHOTREXATe and DOXOrubicin]
  312071000210105	SAR - MAP [metHOTREXATe, DOXOrubicin and cISplatin]
  312061000210104	SAR Osteosarcoma - MAP [metHOTREXATe, DOXOrubicin and cISplatin]
  312051000210102	PCN MM - pamidronate 90mg Q4W
  312041000210100	LEU ALL precursor B-cell - blinatumomab [CNS1 and CNS2]
  312031000210108	LEU ALL precursor B-cell - blinatumomab [CNS3]
  312021000210106	CRC REC Locally advanced - dostarlimab
  312011000210101	CRC - mFOLFOX6 [low dose foliNIc acid] 9 cycles
  312001000210103	CRC - mFOLFOX6 [high dose foliNIc acid] 9 cycles
  311991000210101	CRC - CAPOX 6 cycles
  311981000210103	CRC REC Neoadjuvant - RAPIDO Total Neoadjuvant Therapy
  311971000210100	CRC Metastatic - irinotecan [Q3W] dose reduced
  311961000210106	CRC Metastatic - CETUximab Q2W
  311951000210108	CRC Metastatic - trifluridine/tipiracil and beVACizumab
  311941000210105	CRC Metastatic - trifluridine/tipiracil
  311931000210102	CRC Metastatic - pembrolizumab Q6W [flat dosing]
  311921000210104	CRC Locally advanced - ipilimumab and nivolumab
  311911000210109	CRC Metastatic - pembrolizumab Q3W [flat dosing]
  311901000210107	CRC Metastatic - CETUximab [Q2W] and encorafenib
  311891000210106	CRC Metastatic - CETUximab [Q2W] and daBRAFEnib
  311881000210109	LEU - AIDA consolidation 3 [70 years and under]
  311871000210107	LEU - AIDA consolidation 2 [70 years and under]
  311861000210101	LEU - AIDA consolidation 1 [70 years and under]
  311851000210104	LEU - AIDA induction [70 years and under]
  311841000210102	LEU APL - AIDA induction and consolidations 1, 2 and 3 [70 years and under]
  311831000210105	LEU - arsenic trioxide and tretinoin consolidation [AML17]
  311821000210108	LEU - arsenic trioxide and tretinoin induction [AML17]
  311811000210103	LEU APL - arsenic trioxide and tretinoin induction followed by consolidation [AML17]
  311801000210100	LEU - APML4 maintenance [61 to 70 years]
  311791000210104	LEU - APML4 consolidation 2 [61 to 70 years]
  311781000210101	LEU - APML4 consolidation 1 [61 to 70 years]
  311771000210103	LEU - APML4 induction [61 to 70 years]
  311761000210109	LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [61 to 70 years]
  311751000210106	LEU - APML4 maintenance [over 70 years]
  311741000210108	LEU - APML4 consolidation 2 [over 70 years]
  311721000210102	LEU - APML4 consolidation 1 [over 70 years]
  311711000210107	LEU - APML4 induction [over 70 years]
  311701000210105	LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [over 70 years]
  311691000210105	LEU - Pethema LPA2005 maintenance [70 years and under] [intermediate risk]
  311681000210108	LEU - Pethema LPA2005 consolidation 3 [70 years and under] [intermediate risk]
  311671000210106	LEU - Pethema LPA2005 consolidation 2 [70 years and under] [intermediate risk]
  311661000210100	LEU - Pethema LPA2005 consolidation 1 [70 years and under] [intermediate risk]
  311651000210103	LEU - Pethema LPA2005 induction [70 years and under] [intermediate risk]
  311641000210101	LEU APL - Pethema LPA2005 induction and consolidations 1, 2 and 3 followed by maintenance [70 years and under] [intermediate risk]
  311631000210109	LEU HCL - cladribine and RITUximab
  311621000210107	LEU - arsenic trioxide and tretinoin consolidation [standard risk]
  311611000210102	LEU - arsenic trioxide, tretinoin and prEDNISone induction [standard risk]
  311601000210104	LEU APL - arsenic trioxide, tretinoin and prEDNISone induction followed by consolidation [standard risk]
  311591000210109	LEU - APML4 maintenance [60 years and under]
  311581000210107	LEU - APML4 consolidation 2 [60 years and under]
  311571000210105	LEU - APML4 consolidation 1 [60 years and under]
  311561000210104	LEU - APML4 induction [60 years and under]
  311551000210102	LEU APL - APML4 induction, consolidation 1 and 2 followed by maintenance [60 years and under]
  311541000210100	LEU - UKALL14 with daSATinib Maintenance
  311531000210108	LEU - UKALL14 with daSATinib Consolidation [Cycle 4]
  311521000210106	LEU - UKALL14 with daSATinib consolidation/delayed intensification [Cycle 3]
  311511000210101	LEU - UKALL14 with daSATinib Consolidation [Cycle 1 and 2]
  311501000210103	LEU - UKALL14 with daSATinib Intensification/CNS prophylaxis
  311491000210108	LEU - UKALL14 with daSATinib Phase 2 Induction
  311481000210106	LEU - UKALL14 with daSATinib Phase 1 Induction
  311471000210109	LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with daSATinib
  311461000210103	LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Maintenance
  311451000210101	LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Consolidation/delayed intensification [Cycle 3]
  311441000210104	LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Intensification/CNS prophylaxis
  311431000210107	LEU - UKALL14 with RITUximab and daSATinib [not for transplant] Phase 2 Induction
  311421000210105	LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [not for transplant]
  311411000210100	LYM - High dose cytarabine [2000mg/m2 TWICE daily days 1 and 2] Consolidation
  311401000210102	LYM - R-MPV alternating with R-MV
  311391000210100	LYM NHL B-cell PCNSL - R-MPV [RITUximab, metHOTREXATe, procarbazine and vinCRISTine] followed by high dose cytarabine
  311381000210102	LYM - EA [etoposide and cytarabine]
  311371000210104	LYM - MT-R
  311361000210105	LYM NHL B-cell PCNSL - MT-R [metHOTREXate, temozolomide and RITUximab] followed by EA [etoposide and cytarabine]
  311351000210107	LYM NHL B-cell Primary Testicular - high dose metHOTREXATe [CNS prophylaxis]
  311341000210109	LYM NHL B-cell PCNSL - MATRix [metHOTREXATe, cytarabine, thiotepa and RITUximab] Induction
  311331000210101	LEU CLL Relapsed - aLEMTUzumab [subcut]
  311321000210103	LEU CLL - venetoclax and oBINUTUZumab
  311311000210108	LEU CLL - RITUximab and bendamustine
  311301000210106	LEU CLL Relapsed - aLEMTUzumab [IV]
  311291000210107	LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 4]
  311281000210105	LEU - UKALL14 with RITUximab and daSATinib consolidation/delayed intensification [Cycle 3] [for transplant]
  311271000210108	LEU - UKALL14 with RITUximab and daSATinib Consolidation [Cycle 1 and 2]
  311261000210102	LEU - UKALL14 with RITUximab and daSATinib [for transplant] Intensification/CNS prophylaxis
  311251000210100	LEU - UKALL14 with RITUximab and daSATinib Phase 2 Induction [for transplant]
  311241000210103	LEU - UKALL14 with RITUximab and daSATinib Phase 1 Induction
  311231000210106	LEU - dexamethasone 6 mg/m2 days 1 to 5
  311221000210109	LEU ALL precursor B-cell BCR-ABL1+ - UKALL14 with RITUximab and daSATinib [for transplant]
  311211000210104	LYM - oBINUTUZumab maintenance
  311201000210101	LYM - bendamustine and oBINUTUZumab
  311191000210103	LYM NHL B-cell - bendamustine and oBINUTUZumab
  311181000210100	LYM NHL NK/T-cell Extra Nodal - DDGP [dexamethasone, cISplatin, gemcitabine and pegaspargase]
  311171000210102	LEU CLL - venetoclax and RITUximab
  311161000210108	LEU - imatinib 600
  311151000210105	LEU - imatinib 400
  311141000210107	LEU CML - imatinib
  311131000210104	LYM NHL B-cell - Flyer R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone] followed by RITUximab
  311121000210101	LEU - UKALL60+ Maintenance
  311111000210106	LEU - UKALL60+ Consolidation
  311101000210109	LEU - UKALL60+ Phase 2 Induction
  311091000210102	LEU - UKALL60+ Phase 1 Induction
  311081000210104	LEU ALL - UKALL60+ [non-intensive]
  311071000210101	LEU - UKALL60+ with daSATinib Maintenance
  311061000210107	LEU - UKALL60+ with daSATinib Consolidation
  311051000210109	LEU - UKALL60+ with daSATinib Phase 2 Induction
  311041000210106	LEU - UKALL60+ with daSATinib Phase 1 Induction
  311031000210103	LEU ALL BCR-ABL1+ - UKALL60+ with daSATinib
  311021000210100	LEU - UKALL60+ with imatinib Maintenance
  311011000210105	LEU - UKALL60+ with imatinib Consolidation
  311001000210108	LEU - UKALL60+ with imatinib Phase 2 Induction
  310991000210109	LEU - UKALL60+ with imatinib Phase 1 Induction
  310981000210107	LEU - dexamethasone 6 mg/m2 [max 10 mg] days 1 to 5
  310971000210105	LEU ALL BCR-ABL1+ - UKALL60+ with imatinib
  310961000210104	LEU AML - DA+GO-2 [DAUNOrubicin, cytarabine and Mylotarg [gemtuzumab ozogamicin]] induction [de novo CD33+] [good or intermediate risk]
  310951000210102	LEU AML - 7 + 3 IDA [IDArubicin and cytarabine] induction
  310941000210100	LEU - High dose cytarabine [1000mg/m2 TWICE daily days 1 to 6] consolidation
  310931000210108	LEU - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction [over 60 years]
  303631000210108	LEU AML - DA[45] 3+7 [DAUNOrubicin and cytarabine] induction followed by high dose cytarabine consolidation [over 60 years]
  303621000210106	LEU - High dose cytarabine and midostaurin consolidation [under 60 years]
  303611000210101	LEU - DAUNOrubicin, cytarabine and midostaurin induction [under 60 years]
  303601000210103	LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [under 60 years]
  303591000210108	LEU - Midostaurin maintenance
  303581000210106	LEU - High dose cytarabine and midostaurin consolidation [60 years and over]
  303571000210109	LEU - DAUNOrubicin, cytarabine and midostaurin induction [60 years and over]
  303561000210103	LEU AML - DAUNOrubicin, cytarabine and midostaurin induction, high dose cytarabine and midostaurin consolidation followed by midostaurin maintenance [FLT3 mutated] [60 years and over]
  303551000210101	LEU - Manchester Protocol [mitoxantrone and cytarabine IV] consolidation
  303541000210104	LEU - Manchester Protocol [mitoxantrone and cytarabine IV] induction
  303531000210107	LEU AML - Manchester Protocol [mitoxantrone and cytarabine IV] induction followed by consolidation
  303521000210105	LYM NHL B-cell PCNSL Relapsed - R-IE [RITUximab, IFOSFamide and etoposide]
  303511000210100	LYM - procarbazine [100 mg daily for 5 days]
  303501000210102	LYM - R-MP [RITUximab, metHOTREXATe, procarbazine] [65 years and over]
  303491000210107	LYM NHL B-cell PCNSL - R-MP [RITUximab, metHOTREXATe and procarbazine] followed by procarbazine maintenance [65 years and over]
  303481000210105	LYM NHL B-cell - RITUximab and bendamustine
  303471000210108	LYM NHL B-cell - RITUximab Maintenance Q8W
  303461000210102	LYM NHL B-cell - RITUximab Q1W
  303451000210100	GYN CX Advanced - cISplatin, PACLItaxel, beVACizumab and pembrolizumab
  303441000210103	GYN CX Advanced - cISplatin, PACLItaxel and pembrolizumab
  274651000210101	GYN CX Advanced - cISplatin, PACLItaxel and beVACizumab
  265811000210107	LYM NHL - vinCRISTine and prEDNISone [pre-phase]
  265801000210105	LYM NHL B-cell PCNSL - high dose metHOTREXATe 8 g/m2
  265791000210106	LYM NHL B-cell - CYCLOPHOSPHamide and prEDNIsone [pre-phase]
  265781000210109	LYM Relapsed - GIVE [filgrastim, IFOSFamide, etoposide and epirubicin]
  265771000210107	LYM Relapsed - DHAP [dexamethasone, high dose cytarabine and cISplatin]
  265761000210101	LYM NHL NK/T-cell Extra Nodal - Level 2 [100%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]
  265751000210104	LYM NHL NK/T-cell Extra Nodal - Level 1 [67%] DeVIC [dexamethasone, etoposide, IFOSFamide, cARBOplatin] chemoradiation [nasal type]
  265741000210102	LYM NHL B-cell Relapsed - R-DHAP [RITUximab, dexamethasone, high dose cytarabine and cISplatin]
  265731000210105	Neuroendocrine neoplasm Advanced - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  265721000210108	Neuroendocrine carcinoma Advanced - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  265711000210103	Neuroendocrine carcinoma - cISplatin and etoposide 60/120 chemoradiation
  265701000210100	Neuroendocrine carcinoma - cISplatin and etoposide 80/100 chemoradiation
  265691000210100	Desmoid fibromatosis - metHOTREXATe and vinBLASTine
  265681000210102	SAR STS Metastatic - DOCEtaxel and gemcitabine 900
  265671000210104	SAR STS Metastatic - DOCEtaxel and gemcitabine 675 [GeDDis]
  265661000210105	SAR STS Advanced - trabectedin
  265651000210107	SAR STS Advanced - pAZOPanib
  265641000210109	SAR STS Advanced - IFOSFamide [3-day]
  265631000210101	SAR - VC [vinCRISTine and CYCLOPHOSPHamide][Q2W]
  265621000210103	SAR - IE [IFOSfamide and etoposide][Q2W]
  265611000210108	SAR - VDC [vinCRISTine, DOXOrubicin and CYCLOPHOSPHamide] with dexrazoxane [Q2W]
  265601000210106	SAR Ewing sarcoma - VDC with dexrazoxane, VC and IE [Q2W]
  265591000210101	SAR STS Advanced - DOXOrubicin and IFOSFamide 25/3000
  265581000210103	SAR STS Advanced - DOXOrubicin and IFOSFamide 20/2000
  265571000210100	SAR Osteosarcoma Advanced - DOXOrubicin [1-day dosing] and cISplatin
  265561000210106	SAR Ewing sarcoma Relapsed - CYCLOPHOSPHamide and topotecan
  265551000210108	SAR Rhabdomyosarcoma Relapsed - VIT [vinCRISTine, irinotecan and temozolomide]
  265541000210105	SAR Osteosarcoma Advanced - DOXOrubicin [3-day split dosing] and cISplatin
  265531000210102	LYM NHL B-cell - R-MiniCHOP [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
  265521000210104	Neuroendocrine carcinoma Advanced - cARBOplatin and oral etoposide
  265511000210109	Neuroendocrine tumour Advanced - everolimus
  265501000210107	Neuroendocrine tumour PANC Advanced - sUNITinib
  265491000210102	Neuroendocrine carcinoma Advanced - cARBOplatin and etoposide
  265481000210104	GU Renal cell Metastatic - beVACizumab and erlotinib
  265471000210101	GU GCT Advanced - EP [etoposide and cISplatin] [3-day]
  265461000210107	GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [3-day]
  265451000210109	GU Bladder Urothelial - cISplatin [Q1W] chemoradiation
  265441000210106	GU URO Advanced - avelumab Q2W [flat dosing]
  265431000210103	GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab
  265421000210100	GU Renal cell Metastatic - cABOZANtinib and nivolumab
  265411000210105	GU Renal cell Metastatic - aXITinib and avelumab [flat dose]
  265401000210108	GU - nivolumab maintenance Q2W [flat dosing]
  265391000210105	GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q2W [flat dosing]
  265381000210108	GU - nivolumab maintenance Q4W [flat dosing]
  265371000210106	GU - nivolumab and ipilimumab induction
  265361000210100	GU Renal cell Advanced - nivolumab and ipilimumab induction followed by nivolumab maintenance Q4W [flat dosing]
  265351000210103	GU URO Metastatic - PACLItaxel Q1W and pembrolizumab Q3W [flat dosing]
  265341000210101	GU Renal cell Metastatic - leNVAtinib and everolimus
  265331000210109	GU Bladder Urothelial - gemcitabine [low dose] chemoradiation
  265321000210107	GU Bladder Urothelial Neoadjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense
  265311000210102	GU Bladder Urothelial Adjuvant - ddMVAC [metHOTREXATe, DOXOrubicin, vinBLASTine and cISplatin] dose dense
  265301000210104	GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [3-day]
  265291000210103	GU Penile Advanced - TIP [PACLItaxel, IFOSFamide and cISplatin] [5-day]
  265281000210100	GU Penile Advanced - TPF [DOCEtaxel, cISplatin, fluorouracil]
  265271000210102	CRC ACA - cISplatin and fluorouracil chemoradiation
  265261000210108	CRC ACA - mitomycin and capecitabine chemoradiation
  265251000210105	CRC ACA - mitomycin and fluorouracil chemoradiation
  265241000210107	UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and nivolumab
  265231000210104	UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin], pembrolizumab and trastuzumab
  265221000210101	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and nivolumab
  265211000210106	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and nivolumab
  265201000210109	CRC Metastatic - CETUximab [Q1W], daBRAFEnib and tRAMEtinib
  265191000210107	GU URO Metastatic - PACLItaxel [Q1W]
  265181000210105	GU Renal cell Metastatic - leNVAtinib and pembrolizumab Q3W [flat dosing]
  265171000210108	GU Renal cell Advanced - nivolumab Q2W [flat dosing]
  265161000210102	GU Renal cell Advanced - nivolumab Q4W [flat dosing]
  265151000210100	GU Renal cell Metastatic - pAZOPanib
  265141000210103	GU Renal cell Metastatic - sUNITinib
  265131000210106	GU URO Advanced - pembrolizumab Q3W [flat dosing]
  265121000210109	GU URO Advanced - pembrolizumab Q6W [flat dosing]
  265111000210104	GU Renal cell Metastatic - aXITinib and pembrolizumab Q3W [flat dosing]
  265101000210101	GU Renal cell Metastatic - aXITinib and pembrolizumab Q6W [flat dosing]
  265091000210108	GU Renal cell Metastatic - everolimus
  265081000210106	GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing]
  265071000210109	GU Renal cell Metastatic - pembrolizumab Q6W [flat dosing]
  265061000210103	GU Bladder Urothelial Neoadjuvant - cISplatin and gemcitabine
  265051000210101	GU BLA - mitomycin and fluorouracil chemoradiation
  265041000210104	GU GCT Metastatic - BEP [bleomycin, etoposide and cISplatin] [5-day]
  265031000210107	GU GCT Non-seminoma Adjuvant - BEP [bleomycin, etoposide and cISplatin]
  265021000210105	GU GCT Advanced - EP [etoposide and cISplatin] [5-day]
  265011000210100	GU GCT Metastatic - VIP [etoposide, IFOSFamide and cISplatin]
  265001000210102	GU URO Advanced - cARBOplatin and gemcitabine
  264991000210108	GU Upper Tract Urothelial Adjuvant - cARBOplatin and gemcitabine
  264981000210106	GU Upper Tract Urothelial Adjuvant - cISplatin and gemcitabine
  264971000210109	GU Renal cell Metastatic - cABOZANtinib
  264961000210103	GU Renal cell Metastatic - aXITinib
  264951000210101	LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing]
  264941000210104	LEU CML - pONATinib
  264931000210107	LYM - GemOx [gemcitabine and oxaliplatin]
  264921000210105	LYM Relapsed - DHAC [dexamethasone, high dose cytarabine and cARBOplatin]
  264911000210100	LYM NHL B-cell Relapsed - R-DHAC [RITUximab, dexamethasone, high dose cytarabine and cARBOplatin]
  264901000210102	LYM NHL B-cell PCNSL Relapsed - modified CYVE [cytarabine and etoposide]
  264891000210103	MPN Myelofibrosis - ruxolitinib
  264881000210100	LEU HCL - RITUximab
  264871000210102	LEU T-PLL Relapsed - pentostatin
  264861000210108	LEU T-PLL - aLEMTUzumab [IV]
  264851000210105	LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [3 day]
  264841000210107	LEU CLL - FCR [fludarabine, CYCLOPHOSPHamide and RITUximab] [oral] [5 day]
  264831000210104	LEU CLL - FCR [IV] fludarabine, CYCLOPHOSPHamide and RITUximab
  264821000210101	LEU CLL - venetoclax
  264811000210106	LEU - daSATinib 140
  264801000210109	LEU - daSATinib 100
  264791000210105	LEU CML - daSATinib
  264781000210108	LEU HCL - cladribine
  264771000210106	PCN MM - lenalidomide and dexamethasone
  264761000210100	GYN VUL Advanced - ciSplatin [Q1W] chemoradiation
  264751000210103	LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and gemcitabine
  264741000210101	LUNG NSCLC Locally advanced/Metastatic - cARBOplatin and vinORELBine
  264731000210109	SAR Ewing sarcoma Relapsed - irinotecan and temozolomide
  264721000210107	Desmoid fibromatosis - metHOTREXATe and vinORELBine
  264711000210102	SAR Advanced - pembrolizumab Q3W [flat dosing]
  264701000210104	SAR Advanced/Metastatic - pembrolizumab Q6W [flat dosing]
  264691000210104	SAR Angiosarcoma Advanced - PACLItaxel
  264681000210101	SAR Advanced - pembrolizumab Q3W [weight-based dosing]
  264671000210103	Giant Cell tumour of bone - denosumab
  264661000210109	SAR STS Advanced - DOXOrubicin
  264651000210106	SAR Kaposi Sarcoma - pegylated liposomal DOXOrubicin hydrochloride
  264641000210108	LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]
  264631000210100	LYM NHL T-cell - CHOEP21 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]
  264621000210102	LYM NHL B-cell - R-CVP [RITUximab, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]
  264611000210107	LYM NHL B-cell - R-CHOP21 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
  264601000210105	LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNISone] [IV etoposide]
  264591000210100	LYM NHL B-cell Diffuse large - R-CEOP [RITUximab, CYCLOPHOSPHamide, etoposide, vinCRISTine and prEDNIsone] [IV/oral etoposide]
  264581000210102	LYM - vinORELBine and gemcitabine
  264571000210104	LYM NHL - CHOP21 [CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
  264561000210105	LYM NHL B-cell - R-CHOP14 [RITUximab, CYCLOPHOSPHamide, DOXOrubicin, vinCRISTine and prEDNISone]
  264551000210107	LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV/oral etoposide]
  264541000210109	LYM NHL B-cell - R-CEPP [RITUximab, CYCLOPHOSPHamide, etoposide, procarbazine and prEDNISone] [IV etoposide]
  264531000210101	LYM NHL B-cell - R-GDP [RITUximab, gemcitabine, dexamethasone and cISplatin]
  264521000210103	LYM NHL B-cell - R-GCVP [RITUximab, gemcitabine, CYCLOPHOSPHamide, vinCRISTine and prEDNISone]
  264511000210108	LYM - GDP [gemcitabine, dexamethasone and cISplatin]
  264501000210106	LYM - GCD [gemcitabine, cARBOplatin and dexamethasone]
  264491000210101	LYM NHL B-cell - R-GemOX [RITUximab, gemcitabine and oxaliplatin]
  264481000210103	LYM - PEP-C [prEDNISone, CYCLOPHOSPHamide, etoposide and procarbazine]
  264471000210100	CRC ACA Advanced - cARBOplatin and PACLItaxel
  264461000210106	CRC Metastatic - CETUximab [Q1W], biNIMEtinib and encorafenib
  264451000210108	CRC Metastatic - CETUximab [Q1W] and encorafenib
  264441000210105	LEU AML - MidAC [mitoxantrone and cytarabine]
  264431000210102	LEU CLL - acalabrutinib
  264411000210109	LEU CLL - chlorambucil and oBINUTUZumab
  264401000210107	LEU - nilotinib 300
  264391000210109	LEU - nilotinib 400
  264381000210107	LEU CML - nilotinib
  264371000210105	CNS GBM Recurrent - beVACizumab and irinotecan 340 mg/m2
  264361000210104	LYM Relapsed - ICE [fractionated IFOSFamide, cARBOplatin and etoposide]
  264351000210102	LYM NHL B-cell Relapsed - R-ICE [RITUximab, fractionated IFOSFamide, cARBOplatin and etoposide]
  264341000210100	LYM NHL B-cell MCL - R-BAC [RITUximab, bendamustine and cytarabine]
  264331000210108	LYM NHL B-cell Lymphoplasmacytic - ibrutinib [Waldenström macroglobulinema]
  264321000210106	LYM HL Advanced - ChlVPP [chlorambucil, vinBLASTine, procarbazine and prEDNISone]
  264311000210101	LYM NHL B-cell MCL - ibrutinib
  264301000210103	LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV/oral etoposide]
  264291000210102	LYM NHL T-cell - CHOEP14 [CYCLOPHOSPHamide, DOXOrubicin, etoposide, vinCRISTine and prEDNISone] [IV etoposide]
  264281000210104	CNS GBM Recurrent - lomustine
  264271000210101	CNS GLI Recurrent - temozolomide [continuous dose-intense] [high grade]
  264261000210107	CNS GBM Recurrent - beVACizumab and irinotecan 125 mg/m2
  264251000210109	CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [high grade]
  264241000210106	CNS GLI Adjuvant - PCV [procarbazine, lomustine and vinCRISTine] [low grade]
  264231000210103	LUNG NSCLC Metastatic - vinORELBine 30 [day 1 and 8] Q3W
  264221000210100	LUNG NSCLC Metastatic - vinORELBine 25 Q1W
  264211000210105	BR Adjuvant - EC-D [epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
  264201000210108	BR Metastatic - olaparib
  264191000210106	BR NON-Metastatic - D100-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]
  264181000210109	BR Neoadjuvant - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
  264171000210107	BR NON-Metastatic - D75-FEC [DOCEtaxel followed by fluorouracil, epirubicin and CYCLOPHOSPHamide]
  264161000210101	BR NON-Metastatic - EC [epirubicin and CYCLOPHOSPHamide]
  264151000210104	LEU AML Relapsed - gilteritinib [FLT3 mutated]
  264141000210102	LEU AML Refractory - FLAG-Ida10 [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]
  264131000210105	LEU AML FLT3-ITD mutated Relapsed - azacitidine and soRAFENib
  264121000210108	LEU AML FLT3-ITD mutated - soRAFENib maintenance after allogeneic stem cell transplant
  264111000210103	LEU AML - azacitidine [7 day]
  264101000210100	LEU AML - azacitidine and venetoclax
  264091000210107	LEU AML - ALFA 9801 [IDArubicin and cytarabine] induction
  264081000210105	LEU AML - MACE [amsacrine, cytarabine and etoposide]
  264071000210108	LUNG NSCLC Locally advanced - durvalumab Q4W [flat dosing]
  264061000210102	PCN MM Relapsed - carfilzomib and dexamethasone [Q1W]
  264051000210100	PCN MM Relapsed - pomalidomide and dexamethasone
  264041000210103	PCN MM Relapsed - daratumumab [subcut]
  264031000210106	PCN MM Relapsed - daratumumab [subcut], bortezomib and dexamethasone [Q3W] followed by daratumumab [subcut] [Q4W]
  264021000210109	PCN MM Relapsed - LenBorDex [lenalidomide, bortezomib, and dexamethasone] Q4W
  264011000210104	PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone
  264001000210101	Myelodysplastic syndrome - azacitidine [7 day]
  263991000210105	Myelodysplastic syndrome - azacitidine [5 day]
  263981000210108	LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [60 years and over]
  263971000210106	CNS GBM Recurrent - beVACizumab and lomustine
  263961000210100	CNS GBM Recurrent - beVACizumab Q2W
  263951000210103	CNS GBM Recurrent - beVACizumab Q3W
  263941000210101	CNS GLI Recurrent - temozolomide [high grade]
  263931000210109	CNS - temozolomide following chemoradiation
  263921000210107	CNS - temozolomide chemoradiation
  263911000210102	CNS GBM - temozolomide chemoradiation followed by temozolomide
  263901000210104	LUNG NSCLC Metastatic - pembrolizumab Q3W [flat dosing]
  263891000210100	LUNG SCLC Extensive - PACLItaxel Q1W
  263881000210102	LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [under 60 years]
  263871000210104	LEU AML Relapsed - FLAG-amsacrine [fludarabine, cytarabine, filgrastim and amsacrine] [60 years and over]
  263861000210105	LEU AML Relapsed - FLAG [fludarabine, cytarabine and filgrastim] [under 60 years]
  263851000210107	LEU CMML - azacitidine [7 day]
  263841000210109	LEU AML - cytarabine 3 g/m2 [ONCE daily days 1 to 6] consolidation [courses 3 and 4]
  263831000210101	LUNG NSCLC Metastatic - gemcitabine
  263821000210103	LUNG NSCLC Adjuvant - osimertinib
  60491000210104	LEU AML - low dose cytarabine
  60481000210101	LEU AML - low dose cytarabine and venetoclax
  60471000210103	LEU AML - DA 3+8 [DAUNOrubicin and cytarabine] induction [course 2]
  60461000210109	LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1]
  60451000210106	LEU AML - cytarabine 3 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [under 60 years]
  60441000210108	LEU AML - cytarabine 1.5 g/m2 [days 1,3,5] consolidation [courses 3 and 4] [60 years and over]
  60431000210100	LEU AML - cytarabine 3 g/m2 [days 1,2,3] consolidation [courses 3 and 4] [under 60 years]
  60421000210102	LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [under 60 years]
  60411000210107	LEU AML - FLAG-Ida [fludarabine, cytarabine, filgrastim and IDArubicin] [60 years and over]
  60401000210105	PCN MM - daratumumab [subcut], lenalidomide and dexamethasone
  60391000210107	PCN MM - lenalidomide [continuous dosing] post autologous stem cell transplant
  60381000210105	PCN MM - pamidronate 30mg Q4W
  60371000210108	PCN MM - zoledronic acid [Q12W]
  60361000210102	PCN MM - MP [melphalan and preDNISone]
  60351000210100	PCN MM - MPT [melphalan, prEDNISone and thalidomide]
  60341000210103	PCN MM - lenalidomide [3/1 dosing] post autologous stem cell transplant
  60331000210106	PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] consolidation
  60321000210109	PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction followed by autologous stem cell transplant
  60311000210104	PCN MM - ixazomib, lenalidomide and dexamethasone
  60301000210101	PCN MM - CyBorDex Low [CYCLOPHOSPHamide, bortezomib and dexamethasone]
  60291000210100	PCN - CTDa [CYCLOPHOSPHamide, thalidomide and dexamethasone] [attenuated dose]
  60281000210102	PCN MM - CyBorDex High [CYCLOPHOSPHamide, bortezomib and dexamethasone]
  60271000210104	PCN - CTD [CYCLOPHOSPHamide, thalidomide and dexamethasone]
  60261000210105	PCN MM - BTD [bortezomib, thalidomide and dexamethasone] induction
  60251000210107	PCN MM - BMP [bortezomib, melphalan and prEDNISone]
  60241000210109	MPN - busulfan
  60231000210101	HN NPC Metastatic - gemcitabine [Q4W]
  60221000210103	GYN Ovarian germ cell tumour - BEP [bleomycin, etoposide and cISplatin]
  60211000210108	GYN OV Recurrent - PACLitaxel [Q1W] and beVACizumab
  60201000210106	GYN OV Recurrent - PACLitaxel [Q1W]
  60191000210109	CRC Adjuvant - mDe Gramont [high dose foliNIc acid]
  60181000210107	CRC Adjuvant - mDe Gramont [low dose foliNIc acid]
  60171000210105	UGI BIL AND GBC Metastatic - cISplatin and gemcitabine
  60161000210104	UGI PANC Metastatic - gemcitabine and Abraxane [PACLItaxel nanoparticle albumin bound]
  60151000210102	LEU CLL - ibrutinib
  60141000210100	LEU CLL - chlorambucil
  60131000210108	LEU CLL - chlorambucil [flat dosing]
  60121000210106	HN SQCC Metastatic - metHOTREXATe
  60111000210101	HN SQCC NON-Metastatic - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation
  60101000210103	HN SQCC NON-Metastatic - CETUximab chemoradiation
  60091000210105	GYN - cARBOplatin and PACLItaxel [following chemoradiation]
  60081000210108	GYN - cISplatin chemoradiation
  60071000210106	GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel
  60061000210100	GYN OV Recurrent - topotecan
  60051000210103	GYN END Adjuvant - cARBOplatin and PACLItaxel [chemotherapy-only]
  60041000210101	GYN VUL Advanced - CARBOplatin [Q1W] chemoradiation
  60031000210109	GYN OV Recurrent - topotecan and beVACizumab Q4W
  60021000210107	GYN GTD - TP-TE [PACLItaxel, cISplatin - PACLItaxel and etoposide] [relapsed or high risk]
  60011000210102	GYN GTD - EP-EMA [etoposide, ciSplatin, etoposide, metHOTREXATe and daCTINomycin] [high risk]
  60001000210104	GYN OV Low grade serous carcinoma - letrozole maintenance
  59991000210107	GYN OV Recurrent - CYCLOPHOSPHamide oral [2/4 dosing]
  59981000210105	GYN OV Recurrent - CYCLOPHOSPHamide oral [continuous]
  59971000210108	GYN OV Recurrent - etoposide oral
  59961000210102	GYN OV Recurrent - gemcitabine
  59951000210100	GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride
  59941000210103	GYN OV Recurrent - pegylated liposomal DOXOrubicin hydrochloride and beVACizumab
  59931000210106	GYN CX Locally advanced - cARBOplatin [Q1W] chemoradiation
  59921000210109	GYN CX Locally advanced - cISplatin [Q1W] chemoradiation
  59911000210104	GYN GTD - EMA-CO [etoposide, metHOTREXATe, daCTINomycin, CYCLOPHOSPHamide and vinCRISTine] [high risk]
  59901000210101	LUNG NSCLC Locally advanced - durvalumab Q2W [weight based dosing]
  59891000210102	GYN OV Recurrent - cARBOplatin and gemcitabine [day 1 cARBOplatin]
  59881000210104	GYN OV Recurrent - cARBOplatin and pegylated liposomal DOXOrubicin hydrochloride
  59871000210101	GYN OV Recurrent - cARBOplatin, gemcitabine and beVACizumab
  59861000210107	GYN OV Recurrent - cARBOplatin, pegylated liposomal DOXOrubicin hydrochloride and beVACizumab
  59851000210109	GYN GTD - EP [etoposide and cISplatin] [very high risk]
  59841000210106	BR NON-Metastatic - DOCEtaxel, pERTUZumab and trastuzumab
  59831000210103	BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 3/4]
  59821000210100	BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W followed by AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense
  59811000210105	BR Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
  59801000210108	BR Metastatic - vinORELBine [IV], pERTUZumab and trastuzumab Q3W
  59791000210109	BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] [Q1W 2/3]
  59781000210107	BR Metastatic - vinORELBine [oral]
  59771000210105	GYN END Advanced - meDROXYPROGESTERone acetate
  59761000210104	GYN OV Advanced - beVACizumab 7.5 mg/kg Q3W [shared care]
  59751000210102	GYN OV Advanced - cARBOplatin [primary treatment]
  59731000210108	GYN CX Advanced - cISplatin and PACLItaxel
  59721000210106	GYN OV Advanced - cARBOplatin and DOCEtaxel
  59711000210101	GYN OV Advanced - cARBOplatin and PACLItaxel [Q1W]
  59701000210103	GYN OV Advanced - cARBOplatin and PACLitaxel [Q3W]
  59691000210103	GYN OV Advanced - cARBOplatin, PACLItaxel and beVACizumab
  59681000210100	GYN OV Recurrent - cARBOplatin
  59671000210102	GYN OV Advanced - olaparib
  59661000210108	GYN END Advanced - leNVAtinib and pembrolizumab Q3W [flat dosing]
  59651000210105	GYN OV Advanced - beVACizumab 15 mg/kg Q3W [shared care]
  59641000210107	GYN OV Adjuvant - cARBOplatin and PACLitaxel [early stage]
  59631000210104	GYN OV Adjuvant - cARBOplatin [early stage]
  59621000210101	GYN GTD - metHOTREXATe [low risk]
  59591000210104	GYN GTD - daCTINomycin [low risk]
  59581000210101	GYN - pembrolizumab Q3W [weight based dosing]
  59571000210103	GYN - pembrolizumab Q6W [flat dosing]
  59561000210109	GYN - pembrolizumab Q3W [flat dosing]
  59551000210106	GYN END Advanced - cARBOplatin and PACLItaxel
  59541000210108	GYN CX Advanced - cARBOplatin, PACLItaxel and beVACizumab
  59531000210100	GYN CX Advanced - cARBOplatin and PACLItaxel
  59521000210102	LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 80/100 chemoradiation
  59511000210107	HN THY Metastatic - leNVAtinib
  59501000210105	HN SQCC NON-Metastatic - cISplatin [Q3W] post-operative chemoradiation
  59491000210100	HN SQCC Metastatic - cARBOplatin and fluorouracil [Q3W]
  59481000210102	HN NPC NON-Metastatic - cARBOplatin chemoradiation followed by cARBOplatin and fluorouracil
  59471000210104	HN NPC NON-Metastatic - gemcitabine and cISplatin followed by cISplatin chemoradiation
  59461000210105	HN SAL Metastatic - cISplatin and vinORELBine [IV]
  59451000210107	HN SQCC NON-Metastatic - cISplatin [Q3W] chemoradiation
  59441000210109	HN NPC NON-Metastatic - cISplatin [Q3W] chemoradiation followed by cISplatin and fluorouracil
  59431000210101	HN SAL Metastatic - CAP [CYCLOPHOSPHamide, DOXOrubicin and cISplatin]
  59421000210103	HN SQCC Metastatic - cISplatin, fluorouracil and pembrolizumab
  59411000210108	HN SQCC Metastatic - nivolumab Q2W [flat dosing]
  59401000210106	HN SQCC Metastatic - PACLItaxel Q1W
  59391000210108	HN SQCC Metastatic - pembrolizumab Q3W [weight-based dosing]
  59381000210106	HN NPC Metastatic - gemcitabine and cARBOplatin
  59371000210109	HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab
  59361000210103	HN NPC Metastatic - gemcitabine and cISplatin
  59351000210101	HN SQCC Metastatic - cARBOplatin and PACLItaxel
  59341000210104	HN SQCC Metastatic - cISplatin and fluorouracil
  59331000210107	HN NPC NON-Metastatic - cISplatin [Q1W] chemoradiation
  59321000210105	HN SQCC NON-Metastatic - cISplatin [Q1W] chemoradiation
  59311000210100	BR NON-Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
  59301000210102	BR Metastatic - CMF classical IV [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
  59291000210101	LUNG NSCLC NON-Metastatic - cISplatin and gemcitabine chemoradiation
  59281000210103	LUNG NSCLC Metastatic - cISplatin and gemcitabine
  59271000210100	LUNG NSCLC NON-Metastatic - cISplatin and vinBLASTine chemoradiation
  59261000210106	GU PROS Metastatic - zoledronic acid Q6W
  59251000210108	HN SQCC Metastatic - nivolumab Q4W [flat dosing]
  59241000210105	HN SQCC NON-Metastatic - cISplatin [Q1W] post-operative chemoradiation
  59231000210102	HN SQCC NON-Metastatic - cARBOplatin and fluorouracil chemoradiation
  59221000210104	HN SQCC Metastatic - nivolumab [weight-based dosing]
  59211000210109	HN SQCC Metastatic - pembrolizumab Q6W [flat dosing]
  59201000210107	HN SQCC Metastatic - pembrolizumab Q3W [flat dosing]
  59191000210105	BR Metastatic - capecitabine 1000 and trastuzumab Q3W
  59181000210108	BR Metastatic - DOCEtaxel Q3W
  59171000210106	BR Metastatic - DOCEtaxel, pERTUZumab and trastuzumab
  59161000210100	BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W
  59151000210103	BR Metastatic - DOCEtaxel and trastuzumab Q3W
  59141000210101	BR NON-Metastatic - FEC-D75 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
  59131000210109	BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide]
  59121000210107	BR NON-Metastatic - AC-TH [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by [DOCEtaxel and trastuzumab] Q3W
  59111000210102	UGI GAST AND OES Metastatic - DOCEtaxel
  59101000210104	UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  59091000210106	UGI PANC NON-Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  59081000210109	UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  59071000210107	UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  59051000210104	UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  59041000210102	UGI PANC Metastatic - FOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  59031000210105	UGI PANC Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  59021000210108	SKIN Melanoma NON-Metastatic - daBRAFEnib and tRAMEtinib
  59011000210103	LUNG NSCLC Metastatic - gefitinib
  59001000210100	LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide 60/120 chemoradiation
  58991000210100	LUNG SCLC Extensive - cARBOplatin and oral etoposide
  58981000210102	LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q4W
  58971000210104	LUNG SCLC Metastatic - [Extensive] cISplatin and irinotecan
  58961000210105	LUNG SCLC Extensive - cARBOplatin and etoposide
  58951000210107	LUNG NSCLC Metastatic - erlotinib
  58941000210109	LUNG NSCLC Metastatic - cISplatin and pemetrexed
  58931000210101	SKIN Melanoma Metastatic - daBRAFEnib and tRAMEtinib
  58921000210103	LUNG NSCLC NON-Metastatic - cISplatin and vinORELBine Q3W
  58911000210108	LUNG NSCLC Metastatic - cISplatin and vinORELBine
  58901000210106	LUNG NSCLC NON-Metastatic - cARBOplatin and PACLItaxel chemoradiation
  58891000210105	LUNG NSCLC Metastatic - cARBOplatin and PACLItaxel
  58881000210108	BR Metastatic - CYCLOPHOSPHamide and metHOTREXATe [low dose oral]
  58871000210106	BR NON-Metastatic - CMF classical [CYCLOPHOSPHamide, metHOTREXATe and fluorouracil]
  58861000210100	BR NON-Metastatic - AC [DOXOrubicin and and CYCLOPHOSPHamide] dose dense followed by PACLItaxel dose dense
  58851000210103	BR NON-Metastatic - capecitabine
  58841000210101	BR Metastatic - zoledronic acid Q12W
  58831000210109	BR NON-Metastatic - TCy and trastuzumab [DOCEtaxel, CYCLOPHOSPHamide and trastuzumab]
  58821000210107	BR NON-Metastatic - trastuzumab Q3W
  58811000210102	BR NON-Metastatic - trastuzumab subcutaneous
  58801000210104	BR NON-Metastatic - exemestane and goserelin
  58791000210103	BR NON-Metastatic - PACLItaxel Q1W and trastuzumab Q3W
  58781000210100	BR NON-Metastatic - FEC-D100 [fluorouracil, epirubicin and CYCLOPHOSPHamide followed by DOCEtaxel]
  58771000210102	BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] Q3W
  58761000210108	BR NON-Metastatic - zoledronic acid
  58751000210105	BR NON-Metastatic - neratinib
  58741000210107	BR NON-Metastatic - TCH [DOCEtaxel, cARBOplatin and trastuzumab]
  58731000210104	BR NON-Metastatic - PACLItaxel Q1W
  58721000210101	BR NON-Metastatic - Kadcyla [trastuzumab emtansine]
  58711000210106	BR NON-Metastatic - TCy [DOCEtaxel and CYCLOPHOSPHamide]
  58701000210109	BR Metastatic - zoledronic acid Q4W
  58691000210109	BR NON-Metastatic - cARBOplatin Q3W and PACLItaxel Q1W
  58681000210107	BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by PACLItaxel Q1W and trastuzumab Q3W
  58671000210105	BR Metastatic - capecitabine 1250
  58661000210104	BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W followed by DOCEtaxel Q3W
  58651000210102	BR Metastatic - trastuzumab Q3W
  58641000210100	BR Metastatic - DOXOrubicin Q3W
  58631000210108	BR Metastatic - eribulin
  58621000210106	BR Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W
  58611000210101	BR Metastatic - DOXOrubicin Q1W
  58601000210103	BR Metastatic - cARBOplatin [5 AUC] and gemcitabine
  58591000210108	BR Metastatic - gemcitabine
  58581000210106	BR Metastatic - PACLItaxel Q1W and trastuzumab Q3W
  58571000210109	BR Metastatic - pamidronate
  58561000210103	BR Metastatic - goserelin Q12W
  58551000210101	BR Metastatic - pembrolizumab Q3W [flat dosing]
  58541000210104	BR Metastatic - fulvestrant
  58531000210107	BR Metastatic - denosumab
  58521000210105	BR Metastatic - MMM [mitomycin, mitoxantrone and metHOTREXATe]
  58511000210100	BR Metastatic - Kadcyla [trastuzumab emtansine]
  58501000210102	BR Metastatic - PACLItaxel Q1W
  58491000210107	BR Metastatic - everolimus and exemestane
  58481000210105	BR Metastatic - Abraxane [PACLItaxel nanoparticle albumin bound] and aTEZOLIzumab
  58471000210108	BR Metastatic - trastuzumab Q3W and vinORELBine [oral]
  58461000210102	BR Metastatic - trastuzumab Q3W and vinORELBine [IV]
  57851000210102	BR NON-Metastatic - PACLItaxel Q1W, pERTUZumab and trastuzumab Q3W
  57841000210100	BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] Q3W
  57831000210108	BR Metastatic - trastuzumab subcutaneous
  57821000210106	BR Metastatic - vinORELBine [IV]
  57811000210101	BR Metastatic - palbociclib
  57801000210103	BR Metastatic - goserelin Q4W
  57791000210102	BR Metastatic - cARBOplatin
  57781000210104	BR Metastatic - EC [epirubicin and CYCLOPHOSPHamide]
  57771000210101	BR Metastatic - vinORELBine [IV] Q1W
  57761000210107	BR NON-Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide] dose dense
  57751000210109	UGI PANC NON-Metastatic - capecitabine and gemcitabine [advanced]
  57741000210106	UGI PANC NON-Metastatic - capecitabine and gemcitabine [adjuvant]
  57731000210103	UGI PANC NON-Metastatic - mFOLFIRINOX [oxaliplatin, irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  57721000210100	UGI PANC Metastatic - PDXG [DOCEtaxel, gemcitabine, ciSplatin and capecitabine]
  57711000210105	UGI PANC NON-Metastatic - gemcitabine [adjuvant]
  57701000210108	UGI PANC Metastatic - olaparib
  57691000210108	UGI PANC NON-Metastatic - gemcitabine [advanced]
  57681000210106	UGI PANC NON-Metastatic - capecitabine chemoradiation [continuous dosing]
  57671000210109	UGI PANC NON-Metastatic - capecitabine chemoradiation [5 day dosing]
  57661000210103	SKIN SQCC Metastatic - pembrolizumab Q6W [flat dosing]
  57651000210101	SKIN SQCC Metastatic - pembrolizumab Q3W [weight based dosing]
  57641000210104	SKIN SQCC Metastatic - pembrolizumab Q3W [flat dosing]
  57631000210107	SKIN Melanoma NON-Metastatic - pembrolizumab Q6W [flat dosing]
  57621000210105	SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [weight based dosing]
  57611000210100	SKIN Melanoma NON-Metastatic - pembrolizumab Q3W [flat dosing]
  57601000210102	SKIN Melanoma NON-Metastatic - nivolumab Q4W [flat dosing]
  57591000210107	SKIN Melanoma NON-Metastatic - nivolumab Q2W [weight based dosing]
  57581000210105	SKIN Melanoma NON-Metastatic - nivolumab Q2W [flat dosing]
  57571000210108	SKIN Melanoma Metastatic - pembrolizumab Q6W [flat dosing]
  57561000210102	SKIN Melanoma Metastatic - pembrolizumab Q3W [weight based dosing]
  57551000210100	SKIN Melanoma Metastatic - pembrolizumab Q3W [flat dosing]
  57541000210103	SKIN Melanoma Metastatic - nivolumab Q4W [flat dosing]
  57531000210106	SKIN Melanoma Metastatic - nivolumab Q2W [weight based dosing]
  57521000210109	SKIN Melanoma Metastatic - nivolumab Q2W [flat dosing]
  57511000210104	SKIN Melanoma Metastatic - ipilimumab and pembrolizumab
  57501000210101	SKIN Melanoma Metastatic - ipilimumab 3mg/kg and nivolumab 1mg/kg
  57491000210106	SKIN Melanoma Metastatic - ipilimumab 1mg/kg and nivolumab 3mg/kg
  57481000210109	SKIN Melanoma Metastatic - imatinib
  57471000210107	SKIN Melanoma Metastatic - dacarbazine
  57461000210101	SKIN Melanoma Metastatic - cOBIMEtinib and vemurafenib
  57451000210104	SKIN Melanoma Metastatic - cARBOplatin, PACLItaxel, and beVACizumab
  57441000210102	SKIN BCC Metastatic - vismodegib
  57431000210105	SKIN MCC Metastatic - pembrolizumab Q3W [flat dosing]
  57421000210108	SKIN MCC Metastatic - pembrolizumab Q3W [weight based dosing]
  57411000210103	SKIN MCC Metastatic - pembrolizumab Q6W [flat dosing]
  57401000210100	SKIN Melanoma Metastatic - biNIMEtinib and encorafenib
  57391000210103	LUNG SCLC NON-Metastatic - [Limited] cISplatin and etoposide
  57381000210100	LUNG SCLC NON-Metastatic - [Limited] cARBOplatin and etoposide
  57371000210102	LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 750, DOXOrubicin and vinCRISTine]
  57361000210108	UGI HEP Metastatic - leNVAtinib
  57351000210105	UGI HEP Metastatic - aTEZOLIzumab and beVACizumab
  57341000210107	UGI HEP Metastatic - aTEZOLIzumab
  57331000210104	UGI GIST NON-Metastatic - imatinib
  57321000210101	UGI GIST Metastatic - sUNITinib [4/2 dosing]
  57311000210106	UGI GAST Metastatic - cISplatin, capecitabine and pembrolizumab [flat dose]
  57301000210109	UGI GAST AND OES Metastatic - cISplatin, fluorouracil and trastuzumab
  57291000210105	UGI GAST AND OES Metastatic - cISplatin, capecitabine and trastuzumab
  57281000210108	UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  57271000210106	UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  57261000210100	UGI PANC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  54251000210109	UGI GAST AND OES Metastatic - cISplatin and fluorouracil
  54241000210106	UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation
  54231000210103	UGI BIL AND GBC Metastatic - cARBOplatin and gemcitabine
  54221000210100	UGI BIL AND GBC Metastatic - gemcitabine
  54211000210105	UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  54201000210108	UGI GAST AND OES Metastatic - trifluridine/tipiracil
  54191000210106	UGI BIL AND GBC NON-Metastatic - capecitabine
  54181000210109	UGI BIL AND GBC NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  54171000210107	UGI PANC Metastatic - gemcitabine
  54161000210101	UGI GIST Metastatic - sUNITinib [2/1 dosing]
  54151000210104	UGI BIL AND GBC Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  54131000210105	UGI HEP Metastatic - soRAFENib
  54121000210108	UGI GAST AND OES Metastatic - cISplatin and capecitabine
  54111000210103	UGI GAST AND OES Metastatic - pembrolizumab Q3W [weight based dosing]
  54101000210100	UGI GAST AND OES Metastatic - raMUCIRumab
  54091000210107	UGI GAST AND OES Metastatic - PACLItaxel and raMUCIRumab
  54081000210105	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  54071000210108	UGI GAST NON-Metastatic - fluorouracil chemoradiation [modified MacDonald]
  54061000210102	UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  53971000210106	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid] and trastuzumab
  53071000210105	UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  53061000210104	UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin]
  53051000210102	UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  53041000210100	UGI GIST Metastatic - imatinib
  53031000210108	UGI GAST AND OES NON-Metastatic - FLOT [DOCEtaxel, oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid]
  53021000210106	UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation [MSKCC]
  53011000210101	UGI OES NON-Metastatic - mitomycin and fluorouracil chemoradiation
  53001000210103	UGI OES NON-Metastatic - cISplatin and fluorouracil chemoradiation [Herskovic]
  52991000210102	UGI GIST Metastatic - regorafenib
  52981000210104	UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [low dose foliNIc acid]
  52971000210101	UGI GAST AND OES Metastatic - pembrolizumab Q3W [flat dosing]
  52961000210107	UGI GAST NON-Metastatic - CAPOX [capecitabine and oxaliplatin]
  52951000210109	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [high dose foliNIc acid] and trastuzumab
  52941000210106	UGI GAST AND OES Metastatic - CAPOX [capecitabine and oxaliplatin] and trastuzumab
  52931000210103	UGI GAST AND OES NON-Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] chemoradiation [high dose foliNIc acid]
  52921000210100	UGI GAST AND OES Metastatic - irinotecan Q2W
  52911000210105	UGI GAST AND OES Metastatic - PACLItaxel weekly [3/1 dosing]
  52901000210108	UGI GAST AND OES Metastatic - PACLItaxel weekly [continuous dosing]
  52891000210107	UGI GAST AND OES Metastatic - mFOLFOX6 [oxaliplatin, foliNIc acid and fluorouracil] [low dose foliNIc acid]
  52881000210105	UGI OES NON-Metastatic - cARBOplatin and PACLItaxel Q1W chemoradiation
  52871000210108	LUNG SCLC Metastatic - CAV [Extensive] [CYCLOPHOSPHamide 1000, DOXOrubicin and vinCRISTine]
  52861000210102	LUNG NSCLC NON-Metastatic - crizotinib
  52851000210100	LUNG NSCLC NON-Metastatic - cISplatin and etoposide chemoradiation
  52841000210103	LUNG NSCLC NON-Metastatic - [Superior sulcus Pancoast] cISplatin and etoposide chemoradiation
  52831000210106	LUNG NSCLC Metastatic - cARBOplatin and DOCEtaxel
  52821000210109	LUNG NSCLC Metastatic - cARBOplatin and pemetrexed
  52811000210104	LUNG NSCLC Metastatic - DOCEtaxel Q3W
  52801000210101	LUNG NSCLC Metastatic - DOCEtaxel Q1W
  52791000210100	CRC REC Metastatic - capecitabine chemoradiation [continuous dosing]
  52781000210102	LUNG NSCLC NON-Metastatic - durvalumab
  52771000210104	LUNG NSCLC NON-Metastatic - aTEZOLIzumab
  52761000210105	LUNG NSCLC Metastatic - nivolumab Q4W [flat dosing]
  52751000210107	LUNG NSCLC Metastatic - nivolumab Q2W [weight based dosing]
  52741000210109	LUNG NSCLC Metastatic - daBRAFEnib and tRAMEtinib
  52731000210101	LUNG NSCLC Metastatic - aTEZOLIzumab
  52721000210103	LUNG NSCLC Metastatic - aFATinib
  52711000210108	LUNG MESO Metastatic - cISplatin and pemetrexed
  52701000210106	LUNG NSCLC Metastatic - nivolumab Q2W [flat dosing]
  52691000210106	LUNG MESO Metastatic - cARBOplatin and pemetrexed
  52681000210109	LUNG NSCLC Metastatic - PACLItaxel Q1W
  52671000210107	LUNG NSCLC Metastatic - cARBOplatin, pemetrexed and pembrolizumab
  52661000210101	LUNG NSCLC Metastatic - crizotinib
  52651000210104	LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel and pembrolizumab
  52641000210102	LUNG NSCLC Metastatic - cARBOplatin, PACLItaxel, aTEZOLIzumab and beVACizumab
  52631000210105	CRC REC Metastatic - capecitabine chemoradiation [5 day dosing]
  52621000210108	CRC Adjuvant - mRoswell Park [low dose foliNIc acid]
  52611000210103	CRC Metastatic - mDe Gramont [low dose foliNIc acid]
  52601000210100	CRC REC Metastatic - fluorouracil chemoradiation
  52591000210105	CRC Metastatic - mDe Gramont [high dose foliNIc acid]
  52581000210108	BR Metastatic - capecitabine 1000
  52571000210106	LUNG MESO Metastatic - vinORELBine
  52561000210100	GU PROS Castration resistant Metastatic - cARBOplatin and DOCEtaxel
  52551000210103	LUNG NSCLC Metastatic - cARBOplatin and Q1W PACLItaxel
  52541000210101	GU PROS Metastatic - zoledronic acid Q12W
  52531000210109	GU PROS Castration resistant Metastatic - enzalutamide
  52521000210107	GU PROS Metastatic - zoledronic acid Q4W
  52511000210102	GU PROS Castration resistant Metastatic - cabazitaxel Q3W and prEDNISone
  52501000210104	CRC Metastatic - raltitrexed and oxaliplatin
  52491000210109	CRC Adjuvant - mRoswell Park [high dose foliNIc acid]
  52481000210107	CRC Metastatic - mRoswell Park [low dose foliNIc acid]
  52471000210105	CRC Metastatic - raltitrexed
  52461000210104	GU PROS Metastatic - goserelin
  52451000210102	GU PROS Castration resistant Metastatic - abiraterone and dexamethasone
  52441000210100	GU PROS Castration resistant NON-Metastatic - apalutamide
  52431000210108	GU PROS Castration sensitive Metastatic - apalutamide
  52421000210106	GU PROS Metastatic - bicalutamide
  52411000210101	GU PROS Metastatic - flutamide
  52401000210103	LUNG NSCLC NON-Metastatic - alectinib
  52391000210101	GU PROS Castration resistant Metastatic - DOCEtaxel Q2W and prEDNISone
  52381000210103	GU PROS Castration resistant Metastatic - DOCEtaxel Q3W and prEDNISone
  52371000210100	GU PROS Castration sensitive Metastatic - abiraterone and prEDNISone
  52361000210106	GU PROS Castration sensitive Metastatic - DOCEtaxel Q3W
  52351000210108	GU PROS Metastatic - cyproterone
  52341000210105	GU PROS Metastatic - pembrolizumab [flat dose]
  52331000210102	LUNG NSCLC Advanced/Metastatic - alectinib
  52321000210104	GU PROS Castration resistant Metastatic - abiraterone and prEDNISone
  52311000210109	GU PROS Castration resistant Metastatic - abiraterone and prEDNISone [fed state]
  52301000210107	CRC Metastatic - mFOLFOXIRI with beVACizumab [high dose foliNIc acid]
  52291000210108	CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [high dose foliNIc acid]
  52281000210106	CRC Metastatic - mFOLFIRI and CETUximab [Q1W] [low dose foliNIc acid]
  52271000210109	CRC Metastatic - mFOLFOXIRI [high dose foliNIc acid]
  52261000210103	CRC Metastatic - mFOLFOXIRI [low dose foliNIc acid]
  52251000210101	CRC Metastatic - mFOLFOXIRI with beVACizumab [low dose foliNIc acid]
  52241000210104	CRC Metastatic - mRoswell Park [high dose foliNIc acid]
  52231000210107	CRC REC Locally advanced - fluorouracil chemoradiation
  52221000210105	CRC REC Locally advanced - capecitabine chemoradiation [continuous dosing]
  52211000210100	CRC REC Locally advanced - capecitabine chemoradiation [5 day dosing]
  52201000210102	CRC Adjuvant - mFOLFOX6 [low dose foliNIc acid]
  52191000210104	CRC Adjuvant - mFOLFOX6 [high dose foliNIc acid]
  52181000210101	CRC Adjuvant - CAPOX
  52171000210103	CRC Adjuvant - capecitabine
  52161000210109	CRC Metastatic - regorafenib
  52151000210106	CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [low dose foliNIc acid]
  52141000210108	CRC Metastatic - mFOLFOX6 and CETUximab [Q2W] [high dose foliNIc acid]
  52131000210100	CRC Metastatic - mFOLFOX6 and beVACizumab [low dose foliNIc acid]
  52121000210102	CRC Metastatic - mFOLFOX6 and beVACizumab [high dose foliNIc acid]
  52111000210107	CRC Metastatic - mFOLFOX6 [low dose foliNIc acid]
  52101000210105	CRC Metastatic - mFOLFOX6 [high dose foliNIc acid]
  52091000210103	CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [low dose foliNIc acid]
  52081000210100	CRC Metastatic - CAPOX
  52071000210102	CRC Metastatic - capecitabine 1000
  52061000210108	CRC Metastatic - capecitabine 1250
  52051000210105	CRC Metastatic - capecitabine and beVACizumab
  52041000210107	CRC Metastatic - capecitabine and mitomycin
  52031000210104	CRC Metastatic - CAPOX and beVACizumab
  52021000210101	CRC Metastatic - CETUximab [Q1W]
  52011000210106	CRC Metastatic - CETUximab [Q1W] and irinotecan [Q2W]
  52001000210109	CRC Metastatic - CETUximab and irinotecan [Q2W]
  51991000210106	CRC Metastatic - irinotecan Q3W
  51981000210109	CRC Metastatic - IrOX
  51971000210107	CRC Metastatic - mCAPIRI
  51961000210101	CRC Metastatic - mFOLFIRI [high dose foliNIc acid]
  51951000210104	CRC Metastatic - mFOLFIRI [low dose foliNIc acid]
  51941000210102	CRC Metastatic - mFOLFIRI and beVACizumab [high dose foliNIc acid]
  51931000210105	CRC Metastatic - mFOLFIRI and beVACizumab [low dose foliNIc acid]
  51921000210108	CRC Metastatic - mFOLFIRI and CETUximab [Q2W] [high dose foliNIc acid]
  51911000210103	CRC Metastatic - FLOX
  51901000210100	CRC Adjuvant - mQUASAR
  51891000210101	CRC Adjuvant - MAYO
  51881000210103	CRC Metastatic - mQUASAR